Applicants thank Examiner Stockton for the courtesy of the interview conducted by telephone on 3 July 2007, where claim amendments were discussed that would overcome Hussein et al. The claim listing below reflects these amendments.

- The office action of 13 April 2007 rejected claims 1-3 under 35 U.S.C. §102(b) as being anticipated by Hussein et al. {Heterocycles, (1994), 38(5), pages 981-990}. Claims 1-3 are amended herein. No new matter is introduced by the subject amendments as the amended claims are fully supported by the specification and original claims. In view of the claim amendments hereinbelow, applicant contends that Hussein et al. do not teach any compound in claims 1-3. Specifically, Hussein et al. do not teach "aromatic-substituted phenylamino, phenyl(C<sub>1</sub>-C<sub>6</sub>)alkylamino, or phenylcarbonylamino wherein the aromatic substituents are independently 1 to 3 halo, nitro, (C<sub>1</sub>-C<sub>6</sub>) alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or amino" at the R<sup>1</sup> position. See amended claim 1 at h); claim 2 at g); and claim 3 at f).
- Therefore, amended claims 1-3 are clearly free of Hussein et al. Applicants respectfully submit that the amendments submitted herewith place the claims in condition for allowance, or at least in better condition for appeal; accordingly entry of the amendments is respectfully requested.

Applicants thank the Examiner for indicating the elected species of Compound RG-12151 allowable. Claims 4 and 5 are currently objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form. Claims 4-5 are amended herein to conform to the amended subject matter of claims 1-3. For reasons stated above, Applicants believe that claims 1-3 are allowable. Therefore, Applicants respectfully request the claim objections be withdrawn and claims 4-5 be allowed.

Applicant has cancelled non-elected claims 6-17 herein, but reserves the right to file divisional

applications on non-elected subject matter.

5 In view of the amendments and remarks, reconsideration and favorable action on the pending

claims 1-5 is respectfully requested. In the event any matters remain to be resolved in view of

this communication, the Examiner is encouraged to contact the undersigned.

This response is being filed within the 3 month period for reply. Therefore, no fees are believed

due. However, the USPTO is directed and authorized to charge all required fees, except for the

Issue Fee and the Publication Fee, to Deposit Account No. 502860. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

15

10

/Chang-Su Lim/

**Intrexon Corporation** 

Blacksburg, VA 24060

Chang-Su Lim, Ph.D.

Telephone: (540) 808-2767

Registration No. 60,094

Facsimile: (540) 961-1765

60394

Customer Number

25

20

Date: 11 July 2007

3